Table 4.
Characteristics of the included studies.
| Author | Year | Design | Number of Patients | Number of Sessions | Total volume Injected (mL) | Volume Per Session (mL) | Expansion System | Complications | Health Quality of Life |
|---|---|---|---|---|---|---|---|---|---|
| Babin [4] | 2017 | Case report | 1 | 3 | 500 | 166 | None | Infection | “Satisfied” |
| Babovic [23] | 2010 | Case report | 1 | 6 | 1615 | 403.9 | None | 0 | “Satisfied” |
| Bayti [24] | 2015 | Retrospective | 22 | 4.9 | 1421 | NR | BRAVA | 18.2% cytosteatonecrosis | Breast Q: 98% “very satisfied” |
| 4.5% hematoma | |||||||||
| 13.6% donor site irregularity | |||||||||
| Cheng [25] | 2013 | Case report | 1 | 2 | 430 | 215 | BRAVA | 0 | - |
| Costantini [26] | 2013 | Prospective | 2 | 2 | 302 | 100.48 | None | - | - |
| Delaporte [27] | 2009 | Retrospective | 15 | 3 | 600 | - | None | 20% cytosteatonecrosis | 66.7% “very good” |
| Fabiocchi [28] | 2017 | Retrospective | 57 | 3.6 | 640 | 318 | Expander | 0.75% hemorrhage donor site | 64.8% “excellent” |
| 0.75% surgical site infection | |||||||||
| Fitoussi [29] | 2009 | Case report | 1 | 2 | 380 | - | None | - | - |
| Hammer-Hansen [30] | 2015 | Case report | 1 | 7 | 957 | 136.71 | BRAVA | Rash | - |
| Ho Quoc [31] | 2016 | Retrospective | 6 | 790 | - | BRAVA | - | 82% “satisfied” | |
| Ho Quoc [32] | 2019 | Retrospective | 2 | 4 | 474 | 118 | None | - | - |
| Hoppe [33] | 2013 | Retrospective | 28 | 5 | 1020 | 159 | None | 2.59% cytosteatonecrosis | 96% “high |
| 0.74% infection | satifaction” | ||||||||
| 0.74% granuloma | |||||||||
| Jarrah [34] | 2013 | Case report | 1 | 3 | 720 | 240 | None | - | - |
| Kellou [35] | 2019 | Retrospective | 22 | 5.86 | 1490.6 | - | None | 50% hematoma donor site | |
| 22.7% lipolysis, | - | ||||||||
| 44.4% puncture site burn, | |||||||||
| 11% lymphocele (donor site) | |||||||||
| 11% hip phlyctene | |||||||||
| Longo [36] | 2014 | Prospective | 21 | 4 | 439 | 137 | None | - | - |
| Manconi [37] | 2017 | Retrospective | 12 | 3 | 417 | 214 | Expander | 3.2 | - |
| Mestak [38] | 2013 | Case report | 1 | 3 | 815 | 271 | BRAVA | 0 | - |
| Niddam [39] | 2017 | Retrospective | 25 | - | - | - | None | - | Satisfaction rate: 5.8/10 |
| Pannettiere [25] | 2011 | Case report | 1 | 9 | 700 | 78 | None | 0 | - |
| Serra-Renom [40] | 2011 | Case series | 8 | 3 | 400 | 133 | None | 0 | - |
| Stillaert [41] | 2016 | Case series | 8 | 4 | 644 | 160 | Expander | 1 cyst | - |
| Zhang [42] | 2020 | Retrospective | 30 | 3,3 | - | 230.5 | +/− BRAVA | 3% cellulitis 27% cysts 3% palpable nodules |
90% “very satisfied” |
Hyphens indicate data not available.